Univasc en es it fr

Univasc Brand names, Univasc Analogs

Univasc Brand Names Mixture

  • No information avaliable

Univasc Chemical_Formula

C66H83N17O13

Univasc RX_link

http://www.rxlist.com/cgi/generic2/nafarelin.htm

Univasc fda sheet

Univasc msds (material safety sheet)

Univasc MSDS

Univasc Synthesis Reference

No information avaliable

Univasc Molecular Weight

1321.6344 g/mol

Univasc Melting Point

No information avaliable

Univasc H2O Solubility

No information avaliable

Univasc State

Solid

Univasc LogP

No information avaliable

Univasc Dosage Forms

Liquid; Metered-dose (aerosol)

Univasc Indication

For treatment of gonadotropin-dependent precocious puberty in children of both sexes and for the treatment of endometriosis.

Univasc Pharmacology

Nafarelin is a potent agonistic analog of gonadotropin-releasing hormone (GnRH). At the onset of administration, nafarelin stimulates the release of the pituitary gonadotropins, LH and FSH, resulting in a temporary increase of gonadal steroidogenesis. Repeated dosing abolishes the stimulatory effect on the pituitary gland. Twice daily administration leads to decreased secretion of gonadal steroids by about 4 weeks; consequently, tissues and functions that depend on gonadal steroids for their maintenance become quiescent. After nafarelin therapy is discontinued, pituitary and ovarian function normalize and estradiol serum concentrations increase to pretreatment levels. Recurrences of endometriosis are frequent after cessation of any hormonal therapy and after surgery that leaves the ovaries and/or uterus intact.

Univasc Absorption

Rapidly absorbed into the systemic circulation after intranasal administration. Bioavailability from a 400 µg dose averaged 2.8% (range 1.2 to 5.6%). Not absorbed after oral administration.

Univasc side effects and Toxicity

In experimental animals, a single subcutaneous administration of up to 60 times the recommended human dose (on a µg/kg basis, not adjusted for bioavailability) had no adverse effects. At present, there is no clinical evidence of adverse effects following overdosage of GnRH analogs.

Univasc Patient Information

Univasc Organisms Affected

Humans and other mammals